• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Medicin
    2. Klinisk medicin och internmedicin
    3. Sjukdomar och rubbningar
    4. Onkologi

    Recombinant Antibodies for Cancer Therapy

    Methods and Protocols

    AvMartin Welschof,Jürgen Krauss

    Inbunden, Engelska, 2002

    Del i serien Methods in Molecular Biology

    1 674 kr

    Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

    Beskrivning

    In Recombinant Antibodies for Cancer Therapy: Methods and Protocols, Martin Welschoff and Jurgen Krauss present a collection of carefully selected protocols for the design, construction, and characterization of novel anticancer therapeutics based on recombinant antibody technology. These readily reproducible methods include coverage of hybridoma-derived recombinant antibodies, recombinant antibody fragments from phagemid-displayed antibody repertoires, antibody fragments with additional properties, and large-scale production of recombinant antibodies for clinical applications. Concise review articles also survey the current status of recombinant antibodies in cancer therapy, as well as the generation of antibody molecules through antibody engineering.

    Produktinformation

    • Utgivningsdatum:2002-09-16
    • Mått:155 x 235 x 27 mm
    • Vikt:874 g
    • Format:Inbunden
    • Språk:Engelska
    • Serie:Methods in Molecular Biology
    • Antal sidor:481
    • Upplaga:2003
    • Förlag:Humana Press Inc.
    • ISBN:9780896039186

    Utforska kategorier

    • Onkologi inom Medicin
    • Biologi inom Naturvetenskap och teknik
    • Naturvetenskap:allmänt inom Naturvetenskap och teknik

    Recensioner i media

    "...the book is well written and the experimental protocols that were included are described in great detail...this book is a valuable resource both for persons new to this field to get an overview of current activities and for those already in the field to look up specific areas that are covered." -Clinical Immunology "Overall the book is a helpful resource, especially for molecular biologists involved in generating antibody fragments, collecting up to date protocols in one convenient volume." - Pharmaceutical Research

    Innehållsförteckning

    • Generation of Antibody Molecules Through Antibody Engineering.- Application of Recombinant Antibodies in Cancer Patients.- Hybridoma-Derived Antibodies.- DNA Immunization as a Means to Generate Antibodies to Proteins.- Chimerization of a Monoclonal Antibody for Treating Hodgkin's Lymphoma.- Humanization of Monoclonal Antibodies by CDR Grafting.- Recombinant Antibody Fragments from Phagemid-Displayed Antibody Repertoires.- Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors.- Construction of Semisynthetic Antibody Libraries.- Single-Domain VH Antibody Fragments from a Phage Display Library.- Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection.- Human Recombinant Fab Antibodies with T-Cell Receptor-Like Specificities Generated from Phage Display Libraries.- Engineering Hot Spots for Affinity Enhancement of Antibodies.- Simultaneous Humanization and Affinity Optimization of Monoclonal Antibodies.- Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries.- Antibody Fragments with Additional Properties.- Engineering scFvs for Improved Stability.- Recombinant Single-Chain and Disulfide-Stabilized Fv Immunotoxins for Cancer Therapy.- Generation of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules.- Construction and Characterization of RNase-Based Targeted Therapeutics.- Bispecific Diabodies for Cancer Therapy.- Generation and Characterization of Bispecific Tandem Diabodies for Tumor Therapy.- Generation of Recombinant Multimeric Antibody Fragments for Tumor Diagnosis and Therapy.- Construction and Characterization of Minibodies for Imaging and Therapy of Colorectal Carcinomas.- Generation, Expression, and Monitoring of Recombinant Immune Receptorsfor Use in Cellular Immunotherapy.- Tailoring Natural Effector Functions.- Single-Chain Fv-Based Affinity Purification of the Cellular Stress Protein gp96 for Vaccine Development.- Recombinant Adenoviruses for In Vivo Expression of Antibody Fragments.- Large Scale Production of Recombinant Antibodies for Clinical Application.- Production of Antibody Fragments in a Bioreactor.- Large Scale Production of Recombinant Antibodies by Utilizing Cellulose-Binding Domains.- Production of Tumor-Specific Antibodies in Tobacco.